A

Amgen

Makes biotech medicines for serious illnesses

Data Management Manager

Full-TimeUpdated on 10/24/2026
No salary listed
Expert
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
Data & AnalyticsData Management

About the job

Requirements
  • A Master's degree and 4 to 6 years of data management experience, or a Bachelor's degree and 8 to 10 years of relevant data management experience.
  • Proven experience working in global teams across time zones and cultures.
  • Proven experience working in Product teams and delivering high-quality solutions in adherence with established processes.
  • Strong leadership, stakeholder management, and communication skills.
  • Excellent oral and written English communication.
  • Prior experience and success working in high-performing data management teams, demonstrating collaboration, innovation, and continuous improvement.
  • Prior experience leading and supporting Data Platforms Operations, including executing in Agile Product teams and overseeing phased execution of Platform enhancements and innovations.
  • Prior experience executing major data transformation projects with global teams, including core teams located in India.
  • Prior experience in data architecture, data flow design, data modelling, and data profiling.
  • Hands-on experience and expertise with AWS and Databricks, including root cause analysis and planning and implementing long-term remediation.
  • Hands-on experience with data analysis using SQL, Python, R, or similar tools and technologies.
  • Prior experience partnering with stakeholders and technology teams in solution design for small features and complex large programs.
  • Ability to learn new concepts, such as end-to-end Commercial data flows, to identify and remediate interdependencies.
  • Ability to collaborate with peers and teams in India and the USA to stay current on industry trends, best practices, and emerging technologies in data acquisition, and to build multi-year data platform roadmaps.
  • Alignment with best practices and commitment to adopting innovative methodologies and tools to enhance data strategies and solutions and drive business outcomes.
  • Strong oral, written, and presentation skills, including the ability to clearly explain complex concepts and controversial findings.
Responsibilities
  • Lead and oversee prioritization, execution, and deployment of features in a Commercial Data Platforms Product team in alignment with standard operating procedures.
  • Lead stages of the software development life cycle as a member of the Data Management Operations teams, including stakeholder requirements gathering across the US Commercial Organization, design, testing, and documentation in partnership with Technology teams in a Product Team setting.
  • Partner with peer teams in the US and Technology teams to review requests, design solutions, estimate effort, and prioritize requests in the assigned Product backlog.
  • Communicate with stakeholders throughout the software development life cycle and align stakeholders and management on effort, solutions, timelines, and expectations.
  • Ensure governance processes are followed, system testing and user acceptance testing are completed, and documentation supports traceability throughout deployment.
  • Work with syndicated data sets, including IQVIA DDD, Xponent, and ELAAD; digital marketing patient- and physician-level data sets; and internal HR, CRM call activity, and Patient Hub data to build HCP- and patient-centric connected data sets.
  • Build connected data products for Amgen's Commercial Data and Analytics function using these data sets to provide insight into prescriber and patient behavior and engagement patterns and support more efficient targeting algorithms.
  • Manage the Big Data platform infrastructure built on AWS, Airflow, and Databricks, including platform access, costs, ad hoc user capabilities, and data quality.
  • Partner with US and Technology teams to evaluate and implement tools and technologies for the platform's future state, including automated anomaly detection, automated document generation, bots against data, data asset searchability, large language models on data and documents, and other generative AI capabilities.
  • Partner with Technology teams and direct line management to implement processes for monitoring system health, alerting on anomalies, and proactively remediating infrastructure concerns.
  • Partner with peers across Master Data Management, Data Platforms, Patient Data Management, and Data Acquisition & Governance to align stakeholder solutions.
  • Identify and highlight roadblocks, process gaps, and resourcing needs to the Leadership team as part of continuous improvement efforts.
  • Identify continuous improvement opportunities, highlight them to direct line management, and strategize roadmaps for deployment.
  • Partner with the Senior Manager, Data Platforms to develop and oversee transition plans for migrating work to the Amgen India Innovation Center with minimal disruption and to establish standard onboarding processes.
  • Execute the insourcing of Operational Data Management Services delivered by external vendors, including knowledge transfer, risk mitigation, and operational readiness.
  • Build a repository of knowledge transition documents and establish processes for efficient operations within a global team framework.
  • Partner with peers in Commercial Data Strategy core pillars and the Data Management Senior Manager to deliver priority initiatives and establish new ways of working, especially across time zones.
  • Work with Technology/IT partners and US team members in a Product Team setting, and partner with other Product teams to align deliverables with the Platform governance model.
  • Act as a liaison at the Amgen India Innovation Center with other Customer Data & Analytics teams to align goals, processes, and success measures.
Desired Qualifications
  • Experience in the life sciences commercial data domain, ideally in Data Platforms and Patient Data.
  • Understanding of syndicated commercial data sets and their use cases.
  • Experience working in multinational settings with teams from different countries.
  • Basic understanding of compliance and data privacy requirements.
  • Familiarity with and application of the Scaled Agile Framework (SAFe).
  • Strong data and analytics, critical-thinking, and decision-making abilities.
  • Ability to perform well in a fast-paced, changing environment.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.